{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022\/\/cdn.jsdelivr.net\/qtip2\/2.2.1\/jquery.qtip.min.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/js\/js_YjAJQgxDlFX6S-O02jj9jCrVbrwlY3CGgCg1FzPlvBs.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\nif(typeof window.MathJax === \u0022undefined\u0022) window.MathJax = { menuSettings: { zoom: \u0022Click\u0022 } };\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/js\/js_waP91NpgGpectm_6Y2XDEauLJ8WCSCBKmmA87unpp2E.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.googletagmanager.com\/gtag\/js?id=G-0K57TCX5BY\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\nwindow.dataLayer = window.dataLayer || [];function gtag(){dataLayer.push(arguments)};gtag(\u0022js\u0022, new Date());gtag(\u0022set\u0022, \u0022developer_id.dMDhkMT\u0022, true);gtag(\u0022config\u0022, \u0022G-0K57TCX5BY\u0022, {\u0022groups\u0022:\u0022default\u0022,\u0022anonymize_ip\u0022:true});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022ac\u0022:{\u0022medrxiv;2022.04.03.22273360v1\u0022:{\u0022access\u0022:{\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022medrxiv;2022.04.03.22273360v1\u0022,\u0022apath\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022medrxiv\u0022}},\u0022processed\u0022:[\u0022highwire_math\u0022],\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022medrxiv;2022.04.03.22273360v1\u0022}]},\u0022instances\u0022:\u0022{\\u0022highwire_abstract_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:20,\\u0022height\\u0022:20,\\u0022border\\u0022:1,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-abstract-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-abstract-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022right center\\u0022,\\u0022my\\u0022:\\u0022left center\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022shift\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter click \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}},\\u0022highwire_author_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:15,\\u0022height\\u0022:15,\\u0022border\\u0022:1,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-author-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-author-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022top center\\u0022,\\u0022my\\u0022:\\u0022bottom center\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}},\\u0022highwire_reflinks_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:15,\\u0022height\\u0022:15,\\u0022border\\u0022:1,\\u0022mimic\\u0022:\\u0022top center\\u0022,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-ref-link-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-ref-link-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022bottom left\\u0022,\\u0022my\\u0022:\\u0022top left\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022flip\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}}}\u0022,\u0022qtipDebug\u0022:\u0022{\\u0022leaveElement\\u0022:0}\u0022,\u0022googleanalytics\u0022:{\u0022account\u0022:[\u0022G-0K57TCX5BY\u0022],\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackColorbox\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022\\\/\\\/cdn.jsdelivr.net\\\/qtip2\\\/2.2.1\\\/jquery.qtip.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u00220\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u0022https:\\\/\\\/www.googletagmanager.com\\\/gtag\\\/js?id=G-0K57TCX5BY\u0022:1,\u00221\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/advagg_css\/css__dn-cpI1YtkU_iLHgA5WhlkxgYWyat_IxjF_B-WSYrpE__a9hIbt0eaZ7d5nhwnm2weG8R_2eXK4EvoOx9dOxouHE__QrrGUc7CpljPR5Aph-ukPbcwtK4AWrHGwCEXJ_k1V_c.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/cdn.jsdelivr.net\/qtip2\/2.2.1\/jquery.qtip.min.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/advagg_css\/css__HGACIFBlu2o05y3afvqlt5wrE_5Dn6MXsexfuEpeIwg__t4SOPxucAPoV3Os7g8dXqyMB1HRXQridRJ82X7nE33E__QrrGUc7CpljPR5Aph-ukPbcwtK4AWrHGwCEXJ_k1V_c.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-article-tab-full-text\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 data-highwire-cite-ref-tooltip-instance=\u0022highwire_reflinks_tooltip\u0022 class=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EABSTRACT\u003C\/h2\u003E\u003Cdiv id=\u0022sec-1\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-4\u0022\u003E\u003Cstrong\u003EBackground\u003C\/strong\u003E It is not known whether sotrovimab, a neutralizing monoclonal antibody (mAb) treatment authorized for early symptomatic COVID-19 patients, is effective against the SARS-CoV-2 Delta variant to prevent progression to severe disease and mortality.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-2\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-5\u0022\u003E\u003Cstrong\u003EMethods\u003C\/strong\u003E Observational cohort study of non-hospitalized adult patients with SARS-CoV-2 infection from October 1\u003Csup\u003Est\u003C\/sup\u003E 2021 - December 11\u003Csup\u003Eth\u003C\/sup\u003E 2021, using electronic health records from a statewide health system plus state-level vaccine and mortality data. We used propensity matching to select 3 patients not receiving mAbs for each patient who received outpatient sotrovimab treatment. The primary outcome was 28-day hospitalization; secondary outcomes included mortality and severity of hospitalization.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-3\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-6\u0022\u003E\u003Cstrong\u003EResults\u003C\/strong\u003E Of 10,036 patients with SARS-CoV-2 infection, 522 receiving sotrovimab were matched to 1,563 not receiving mAbs. Compared to mAb-untreated patients, sotrovimab treatment was associated with a 63% decrease in the odds of all-cause hospitalization (raw rate 2.1% versus 5.7%; adjusted OR 0.37, 95% CI 0.19-0.66) and an 89% decrease in the odds of all-cause 28-day mortality (raw rate 0% versus 1.0%; adjusted OR 0.11, 95% CI 0.0-0.79), and may reduce respiratory disease severity among those hospitalized.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-4\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-7\u0022\u003E\u003Cstrong\u003EConclusion\u003C\/strong\u003E Real-world evidence demonstrated sotrovimab effectiveness in reducing hospitalization and all-cause 28-day mortality among COVID-19 outpatients during the Delta variant phase.\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-5\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EBACKGROUND\u003C\/h2\u003E\u003Cp id=\u0022p-20\u0022\u003EHigh rates of transmission of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus that causes coronavirus disease of 2019 (COVID-19), persist, especially among unvaccinated individuals or those with waning vaccine or infection-related immunity.[\u003Ca id=\u0022xref-ref-1-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-1\u0022\u003E1\u003C\/a\u003E] Neutralizing monoclonal antibody (mAb) treatment provides immediate passive immunity against SARS-CoV-2. Several mAb products have received emergency use authorization (EUA) from the US Food and Drug Administration[\u003Ca id=\u0022xref-ref-2-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-2\u0022\u003E2\u003C\/a\u003E] based on Phase II\/III randomized clinical trials conducted earlier in the pandemic that demonstrated efficacy towards reduced hospitalization and disease severity among high-risk outpatients.[\u003Ca id=\u0022xref-ref-3-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-3\u0022\u003E3\u003C\/a\u003E-\u003Ca id=\u0022xref-ref-5-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-5\u0022\u003E5\u003C\/a\u003E] Use of mAb products such as sotrovimab for individuals who have recently tested positive for SARS-CoV-2 in the outpatient setting is critical to mitigate virus-driven impact on the health care system and is also an evidence-based treatment strategy to improve COVID-19 outcomes among high-risk individuals.\u003C\/p\u003E\u003Cp id=\u0022p-21\u0022\u003ETrials supporting mAb EUA approval were conducted prior to the emergence of the Delta variant surge in the summer 2021, and the trial assessing sotrovimab efficacy was limited in assessment of clinical outcomes or mortality.[\u003Ca id=\u0022xref-ref-4-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-4\u0022\u003E4\u003C\/a\u003E] Following EUA, however, it becomes more challenging to recruit patients into randomized controlled trials.[\u003Ca id=\u0022xref-ref-6-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-6\u0022\u003E6\u003C\/a\u003E] As new variants such as Delta and Omicron emerge, analysis of real-world data sufficiently robust to evaluate important clinical differences is critical to evaluate treatment effectiveness and inform policy and practice decisions. We previously used a real-world platform to report on mAb efficacy during the Delta variant pandemic phase.[\u003Ca id=\u0022xref-ref-7-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-7\u0022\u003E7\u003C\/a\u003E] That prior report focused on mAbs administered through September 2021, predominantly consisting of casivirimab plus imdevimab (\u223c80%), bamlanivimab (\u223c15%), or bamlanivimab plus etesevimab (\u223c3%). Sotrovimab had been administered to only 0.7% of the overall cohort of patients with the Delta variant. Yet, as of January 24\u003Csup\u003Eth\u003C\/sup\u003E, 2022, sotrovimab is the only still-authorized mAb for outpatient COVID-19 treatment,[\u003Ca id=\u0022xref-ref-8-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-8\u0022\u003E8\u003C\/a\u003E] and thus additional data on its clinical effectiveness is warranted.\u003C\/p\u003E\u003Cp id=\u0022p-22\u0022\u003ETo provide useful data to help inform mAb allocation strategies and related policymaking, we leveraged our novel real-world evidence platform[\u003Ca id=\u0022xref-ref-7-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-7\u0022\u003E7\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-9-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-9\u0022\u003E9\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-10-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-10\u0022\u003E10\u003C\/a\u003E] to assess the clinical impact of sotrovimab therapy on high-risk outpatients with early symptomatic COVID-19 infections during a SARS-CoV-2 Delta predominant period in Colorado (10\/1\/2021 \u2013 12\/11\/2021).[\u003Ca id=\u0022xref-ref-11-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-11\u0022\u003E11\u003C\/a\u003E] This paper reports on the effectiveness of sotrovimab against progression of COVID-19 to severe disease, hospitalization, severity of hospitalization, and death.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-6\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EMETHODS\u003C\/h2\u003E\u003Cdiv id=\u0022sec-7\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EStudy Oversight and Data Sources\u003C\/h3\u003E\u003Cp id=\u0022p-23\u0022\u003EWe conducted a propensity-matched observational cohort study, as part of a statewide implementation\/effectiveness pragmatic trial, in a collaboration between University of Colorado researchers, University of Colorado Health (UCHealth) leaders, and the Colorado Department of Public Health and Environment (CDPHE). The study was approved by the Colorado Multiple Institutional Review Board with a waiver of informed consent. We obtained data from the electronic health record (EHR; Epic, Verona, WI) of UCHealth, the largest health system in Colorado with 13 hospitals around the state and 141,000 annual hospital admissions, using Health Data Compass, an enterprise-wide data warehouse. EHR data were merged with statewide data on vaccination status from the Colorado Comprehensive Immunization Information System and mortality from Colorado Vital Records.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-8\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EPatient Population Studied\u003C\/h3\u003E\u003Cp id=\u0022p-24\u0022\u003EWe included patients diagnosed with SARS-CoV-2 infection between October 1, 2021 and December 11, 2021 allowing for at least 28 days of follow-up (n=10,036) (\u003Cstrong\u003EAppendix Figure 1, Supplement\u003C\/strong\u003E). Patients were identified using an EHR-based date of SARS-CoV-2 positive test (by polymerase chain reaction or antigen) or date of administration of mAb treatment (if no SARS-CoV-2 test result date available). The decision to seek mAb treatment was made by patients and clinicians.[\u003Ca id=\u0022xref-ref-11-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-11\u0022\u003E11\u003C\/a\u003E] We did not exclude patients solely for lack of EUA eligibility based on EHR data, because not all eligibility criteria were consistently available in the EHR. We excluded patients who tested positive for SARS-CoV-2 on the same day of or during hospitalization because they were not eligible for mAb treatment. We also excluded patients missing both a positive test date and a sotrovimab administration date (n=708), or if it had been more than 10 days between the positive test date and sotrovimab administration (n=26), resulting in a cohort of sotrovimab (N = 566) or mAb untreated (N = 9,470) patients.\u003C\/p\u003E\u003Cp id=\u0022p-25\u0022\u003ENearest neighbor propensity matching was conducted using logistic regression with treatment status as the outcome. Approximately three untreated patients (N=1,563) were matched to each sotrovimab-treated patient (N=522).[\u003Ca id=\u0022xref-ref-12-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-12\u0022\u003E12\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-13-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-13\u0022\u003E13\u003C\/a\u003E] Only 42 sotrovimab treated patients were lost due to incomplete covariate data. The propensity model included categorial age, sex, race\/ethnicity, obesity status, immunocompromised status, number of comorbid conditions other than obesity and immunocompromised status, number of vaccinations at time of infection, and insurance status. We assessed effectiveness of matching using standardized mean differences (SMDs) with a threshold of 0.1 with results shown in Appendix Table 2.[\u003Ca id=\u0022xref-ref-14-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-14\u0022\u003E14\u003C\/a\u003E]\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-9\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EOutcomes\u003C\/h3\u003E\u003Cp id=\u0022p-26\u0022\u003EThe primary outcome was all-cause hospitalization within 28 days of a positive SARS-CoV-2 test, obtained from EHR data. Secondary outcomes included 28-day all-cause mortality, emergency department (ED) visit within 28 days, in-hospital disease severity based on maximum level of respiratory support, hospital and intensive care unit (ICU) lengths of stay (LOS) in survivors, rates of ICU admission, and in-hospital mortality. For both hospitalization and ED visits, the index visit was used. When mAb treated patients were missing a SARS-CoV-2 positive date (70.5%), we randomly imputed missing test dates from the distribution of observed time between SARS-CoV-2 to mAb administration.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-10\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EVariable Definitions\u003C\/h3\u003E\u003Cp id=\u0022p-27\u0022\u003EHospitalization was defined as any inpatient or observation encounter documented in the EHR. ED visits were defined as any visit to the ED, with or without an associated inpatient or observation encounter. Presence of comorbid conditions and immunocompromised status were determined as reported previously[\u003Ca id=\u0022xref-ref-7-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-7\u0022\u003E7\u003C\/a\u003E] and described further in the Supplement. The number of comorbid conditions was calculated as the sum of the presence of hypertension, cardiovascular disease, diabetes, pulmonary disease, and renal disease.\u003C\/p\u003E\u003Cp id=\u0022p-28\u0022\u003ECOVID-19 disease severity was estimated using ordinal categories of respiratory support requirements at an encounter level, based on the highest level of support received among the following types (in increasing order): no supplemental oxygen, standard (nasal cannula\/face mask) oxygen, high-flow nasal cannula or non-invasive ventilation, and invasive mechanical ventilation.[\u003Ca id=\u0022xref-ref-15-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-15\u0022\u003E15\u003C\/a\u003E] In-hospital mortality was the highest level of disease severity.\u003C\/p\u003E\u003Cp id=\u0022p-29\u0022\u003ENo virus sequencing results were available on an individual patient basis. However, this analysis focused on a period when the Delta variant was dominant (\u0026gt;99% by state-wide data)[\u003Ca id=\u0022xref-ref-11-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-11\u0022\u003E11\u003C\/a\u003E] and coupled with the timing of sotrovimab EUA and distribution in Colorado. Vaccination status was categorized by the number of vaccinations (0, 1, 2, or \u2265 3) administered prior to the date of the SARS-CoV-2 positive test.\u003C\/p\u003E\u003Cp id=\u0022p-30\u0022\u003EThe variables of interest include treatment status, categorical age in years, sex, race\/ethnicity, insurance status, obesity status, immunocompromised status, number of additional comorbid conditions, and number of vaccinations. Due to small sample sizes, the variables age, race\/ethnicity, insurance status, number of comorbid conditions, and vaccination status were each collapsed to the groups shown in the results tables.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-11\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EStatistical analysis\u003C\/h3\u003E\u003Cp id=\u0022p-31\u0022\u003EFirth\u2019s logistic regression was used to assess the association between treatment and 28-day hospitalization, 28-day mortality, and 28-day ED visits. Firth\u2019s logistic regression (R package logistf V 1.24) addresses estimation issues related to low event rates and complete separation.[\u003Ca id=\u0022xref-ref-16-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-16\u0022\u003E16\u003C\/a\u003E-\u003Ca id=\u0022xref-ref-18-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-18\u0022\u003E18\u003C\/a\u003E] All models were adjusted for age, sex, race\/ethnicity, insurance status, obesity status, immunocompromised status, number of additional comorbid conditions, and number of vaccinations. The unadjusted number needed to treat (NNT) was calculated for hospitalization by treatment status.\u003C\/p\u003E\u003Cp id=\u0022p-32\u0022\u003EDue to the small number of hospitalized participants, descriptive statistics including counts and raw rates were calculated for all secondary outcomes among hospitalized participants, including disease severity, hospital LOS, ICU visit, and ICU LOS.\u003C\/p\u003E\u003Cp id=\u0022p-33\u0022\u003EKaplan-Meier curves were estimated to visually assess cumulative incidence patterns by treatment status for 28-day hospitalization.\u003C\/p\u003E\u003Cp id=\u0022p-34\u0022\u003ETwo sensitivity analyses were performed. First, we repeated the above analysis using only EUA-eligible patients as verified by available EHR data. Second, we repeated the above analysis with a more conservative SARS-CoV-2 imputation approach where all missing positive test dates were imputed as ten days prior to the mAb administration date (the maximum time difference allowed by the EUA). All statistical analyses were performed using R Statistical Software (version 3.6.0; R Foundation for Statistical Computing, Vienna, Austria).[\u003Ca id=\u0022xref-ref-19-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-19\u0022\u003E19\u003C\/a\u003E]\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-12\u0022\u003E\u003Ch2 class=\u0022\u0022\u003ERESULTS\u003C\/h2\u003E\u003Cdiv id=\u0022sec-13\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003ECharacteristics of sotrovimab-Treated and mAb-Untreated Cohorts\u003C\/h3\u003E\u003Cp id=\u0022p-35\u0022\u003EOf 10,036 patients with SARS-CoV-2 infection in the full cohort, 566 subjects received mAbs and 9,470 patients did not (\u003Cstrong\u003EAppendix Table 1, Supplement\u003C\/strong\u003E). In the full cohort, the sotrovimab-treated group generally reflects EUA criteria for use of mAbs, with many being older (33.0% were age \u226565 years vs. 11.4% in mAb-untreated group), more likely to be obese (24.0% vs. 16.8%), or having one or more comorbidities (49.1% vs. 36.5%). Propensity matching eliminated clinically meaningful differences in matching variables between groups (\u003Cstrong\u003E\u003Ca id=\u0022xref-table-wrap-1-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T1\u0022\u003ETable 1\u003C\/a\u003E, Appendix Table 2, Supplement\u003C\/strong\u003E). 522 sotrovimab-treated patients were propensity matched to 1,563 untreated patients.\u003C\/p\u003E\u003Cdiv id=\u0022T1\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/499735\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/499735\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022download-ppt last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/499735\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 1.\u003C\/span\u003E \u003Cspan class=\u0022caption-title\u0022\u003EBaseline Characteristics by Mab Treatment Status for Primary Matched Cohort\u003C\/span\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-36\u0022\u003EThe characteristics of sotrovimab-treated and mAb-untreated patients in the matched cohort are presented (\u003Cstrong\u003E\u003Ca id=\u0022xref-table-wrap-1-2\u0022 class=\u0022xref-table\u0022 href=\u0022#T1\u0022\u003ETable 1\u003C\/a\u003E\u003C\/strong\u003E). The age distribution was similar, with 34% aged \u03b565. The cohort was 56% female, 81% Non-Hispanic white, and 56% had private\/commercial insurance. Hypertension (32%) and pulmonary disease (25%) were the most common comorbid conditions. Notably, 54% had received at least two vaccinations at the time of infection, and 39% had not received any vaccine doses. The mean time from positive SARS-CoV-2 test to administration of sotrovimab treatment was 3.7 days (SD 1.8) in those who did not have an imputed positive test date.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-14\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EHospitalization and Mortality\u003C\/h3\u003E\u003Cp id=\u0022p-37\u0022\u003ESotrovimab treatment was associated with a lower rate of 28-day hospitalization compared to matched mAb-untreated controls (11 [2.1%] vs. 89 [5.7%]), representing a 63% decrease in the adjusted odds of hospitalization (adjusted OR 0.37, 95% CI 0.19-0.68; p \u0026lt; 0.001) (\u003Cstrong\u003E\u003Ca id=\u0022xref-table-wrap-2-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T2\u0022\u003ETable 2\u003C\/a\u003E\u003C\/strong\u003E). The unadjusted NNT for hospitalization for the untreated group was 28. Based on a time-to-event analysis, the benefits associated with reduced hospitalization were largely accrued within 12 days of the positive SARS-CoV-2 test date (\u003Cstrong\u003E\u003Ca id=\u0022xref-fig-1-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F1\u0022\u003EFigure 1\u003C\/a\u003E\u003C\/strong\u003E), or an average of 9 days after sotrovimab treatment. Other factors associated with hospitalization are in Supplemental material (\u003Cstrong\u003EAppendix Table 3, Supplement\u003C\/strong\u003E). Covariates that were associated with increased odds of 28-day hospitalization included age \u2265 65 (p = 0.049), obesity (p \u0026lt; 0.001), and one (p = 0.013) or two or more (p \u0026lt; 0.001) comorbid conditions other than obesity or immunocompromised status (\u003Cstrong\u003EAppendix Table 3, Supplement\u003C\/strong\u003E). Each level of vaccination status (1, 2, or \u2265 3 doses) was significantly associated with decreased odds of hospitalization in comparison to having no vaccine.\u003C\/p\u003E\u003Cdiv id=\u0022T2\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/499729\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/499729\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022download-ppt last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/499729\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 2.\u003C\/span\u003E \u003Cspan class=\u0022caption-title\u0022\u003EPrimary and Secondary Outcomes by Monoclonal Antibody Treatment Status\u003C\/span\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022F1\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2022\/04\/05\/2022.04.03.22273360\/F1.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Cumulative Incidence Plots for All-Cause Hospitalization to Day 28 by Sotrovimab Treatment Status \u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-2023188416\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;\u0026lt;span xmlns=\u0026quot;http:\/\/www.w3.org\/1999\/xhtml\u0026quot; class=\u0026quot;caption-title\u0026quot;\u0026gt;Cumulative Incidence Plots for All-Cause Hospitalization to Day 28 by Sotrovimab Treatment Status\u0026lt;\/span\u0026gt; \u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure 1.\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2022\/04\/05\/2022.04.03.22273360\/F1.medium.gif\u0022 width=\u0022440\u0022 height=\u0022440\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure 1.\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2022\/04\/05\/2022.04.03.22273360\/F1.medium.gif\u0022 width=\u0022440\u0022 height=\u0022440\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2022\/04\/05\/2022.04.03.22273360\/F1.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 1.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2022\/04\/05\/2022.04.03.22273360\/F1.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 1.\u003C\/span\u003E \u003Cspan class=\u0022caption-title\u0022\u003ECumulative Incidence Plots for All-Cause Hospitalization to Day 28 by Sotrovimab Treatment Status\u003C\/span\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-38\u0022\u003EImportantly, all-cause 28-day mortality in the sotrovimab-treated group was 0 (0%) compared to 15 (1.0%) among the mAb-untreated group, equating to an 89% decrease in the mortality odds (adjusted OR 0.11, 95% CI 0.0-0.79 (\u003Cstrong\u003E\u003Ca id=\u0022xref-table-wrap-2-2\u0022 class=\u0022xref-table\u0022 href=\u0022#T2\u0022\u003ETable 2\u003C\/a\u003E\u003C\/strong\u003E). There was not a significant association between sotrovimab treatment and the odds of visiting the ED (adjusted OR 1.12, 95% CI 0.77-1.60).\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-15\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003ESeverity of Hospitalization\u003C\/h3\u003E\u003Cp id=\u0022p-39\u0022\u003EAmong hospitalized patients, 0 of 11 (0%) in the sotrovimab-treated group required invasive mechanical ventilation (IMV) or died in the hospital, compared to 19 of 89 (21.3%) mAb-untreated group (\u003Cstrong\u003E\u003Ca id=\u0022xref-table-wrap-2-3\u0022 class=\u0022xref-table\u0022 href=\u0022#T2\u0022\u003ETable 2\u003C\/a\u003E\u003C\/strong\u003E). We also observed that a higher proportion of sotrovimab-treated patients required no supplemental oxygen or only required standard (low-flow) oxygen in comparison to mAb-untreated patients (72.7% vs. 48.3%). The average hospital length of stay (LOS) for sotrovimab patients was 5.3 (+\/- 5.9) days in comparison to 9.4 (+\/- 10.6) days in the untreated group. Collectively, these data suggest a lower severity of disease among hospitalized sotrovimab-treated patients, although statistical inference was not performed (\u003Cstrong\u003E\u003Ca id=\u0022xref-fig-2-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F2\u0022\u003EFigure 2\u003C\/a\u003E\u003C\/strong\u003E). 2 of 9 (18.2%) sotrovimab-treated patients required ICU level of care, a similar percentage compared to mAb-untreated patients (21.3%).\u003C\/p\u003E\u003Cdiv id=\u0022F2\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2022\/04\/05\/2022.04.03.22273360\/F2.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Maximum Respiratory Support by Monoclonal Antibody Treatment Status among Patients Hospitalized within 28 Days Comparing severity of hospitalizations for n=11 sotrovimab-treated and n=89 mAb-untreated patients, the maximum level of respiratory support appeared lower for sotrovimab-treated patients, but inferential statistics were not able to be performed. Abbreviations: mAb, monoclonal antibody; HFNC, high-flow nasal cannula oxygen; NIV, non-invasive ventilation; IMV, invasive mechanical ventilation\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-2023188416\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;\u0026lt;span xmlns=\u0026quot;http:\/\/www.w3.org\/1999\/xhtml\u0026quot; class=\u0026quot;caption-title\u0026quot;\u0026gt;Maximum Respiratory Support by Monoclonal Antibody Treatment Status among Patients Hospitalized within 28 Days\u0026lt;\/span\u0026gt; Comparing severity of hospitalizations for n=11 sotrovimab-treated and n=89 mAb-untreated patients, the maximum level of respiratory support appeared lower for sotrovimab-treated patients, but inferential statistics were not able to be performed. Abbreviations: mAb, monoclonal antibody; HFNC, high-flow nasal cannula oxygen; NIV, non-invasive ventilation; IMV, invasive mechanical ventilation\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure 2.\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2022\/04\/05\/2022.04.03.22273360\/F2.medium.gif\u0022 width=\u0022440\u0022 height=\u0022250\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure 2.\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2022\/04\/05\/2022.04.03.22273360\/F2.medium.gif\u0022 width=\u0022440\u0022 height=\u0022250\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2022\/04\/05\/2022.04.03.22273360\/F2.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 2.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2022\/04\/05\/2022.04.03.22273360\/F2.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 2.\u003C\/span\u003E \u003Cspan class=\u0022caption-title\u0022\u003EMaximum Respiratory Support by Monoclonal Antibody Treatment Status among Patients Hospitalized within 28 Days\u003C\/span\u003E\u003Cp id=\u0022p-40\u0022 class=\u0022first-child\u0022\u003EComparing severity of hospitalizations for n=11 sotrovimab-treated and n=89 mAb-untreated patients, the maximum level of respiratory support appeared lower for sotrovimab-treated patients, but inferential statistics were not able to be performed.\u003C\/p\u003E\u003Cp id=\u0022p-41\u0022\u003EAbbreviations: mAb, monoclonal antibody; HFNC, high-flow nasal cannula oxygen; NIV, non-invasive ventilation; IMV, invasive mechanical ventilation\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-16\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003ESensitivity Analysis\u003C\/h3\u003E\u003Cp id=\u0022p-42\u0022\u003ENeither restricting the cohort to only patients meeting EUA eligibility criteria based on available EHR data or using a more conservative imputation method for missing date of positive SARS-CoV-2 test materially changed the key results and scientific conclusions (\u003Cstrong\u003EAppendix Tables 4-7, Supplement\u003C\/strong\u003E).\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-17\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EDISCUSSION\u003C\/h2\u003E\u003Cp id=\u0022p-43\u0022\u003EDuring a SARS-CoV-2 Delta variant-predominant period in Colorado, sotrovimab reduced 28-day hospitalization by 63% and all-cause 28-day mortality by 89%. Our study adds to the main prior clinical trial demonstrating sotrovimab efficacy that had limited sample size (n=583), occurred prior to the emergence of the Delta variant, and was underpowered to evaluate the impact of sotrovimab on patient mortality.[\u003Ca id=\u0022xref-ref-4-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-4\u0022\u003E4\u003C\/a\u003E] This data on the effectiveness of sotrovimab to prevent severe COVID-19 disease induced by the Delta variant may be critical given the unpredictable nature of the COVID-19 pandemic. When combined with in vitro data that suggests sotrovimab effectively neutralizes the omicron variant,[\u003Ca id=\u0022xref-ref-20-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-20\u0022\u003E20\u003C\/a\u003E] these data support continued sotrovimab prioritization among outpatient treatment options.\u003C\/p\u003E\u003Cp id=\u0022p-44\u0022\u003EAlthough we do not directly compare sotrovimab effectiveness to other mAbs used during a Delta variant-dominated pandemic phase, it is notable that the adjusted OR for 28-day hospitalization in our study (aOR 0.37) is similar to what we previously reported (aOR 0.48) when casivirimab plus imdevimab, bamlanivimab, or bamlanivimab plus etesevimab use as outpatient mAb therapy were far more common than sotrovimab.[\u003Ca id=\u0022xref-ref-7-4\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-7\u0022\u003E7\u003C\/a\u003E] Further supporting sotrovimab effectiveness against the Delta variant of SARS-CoV-2 is a comparable NNT of 28 to prevent one hospitalization, which we observed despite both an increase in the overall vaccination rate and a lower baseline hospitalization rate among mAb-untreated patients compared to the earlier cohort.[\u003Ca id=\u0022xref-ref-7-5\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-7\u0022\u003E7\u003C\/a\u003E]\u003C\/p\u003E\u003Cp id=\u0022p-45\u0022\u003EOur results are of practical importance for policymakers and clinicians because there have been shortages of mAb supplies and infusion capacity, and as such, demonstrating their effectiveness to reduce hospitalization and mortality against each clinically relevant SARS-CoV-2 variant is crucial.[\u003Ca id=\u0022xref-ref-21-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-21\u0022\u003E21\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-22-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-22\u0022\u003E22\u003C\/a\u003E] Study findings support continued use of sotrovimab for patients with high baseline risk for hospitalization, including those who are older than 65, obese, are not fully vaccinated, or have comorbid conditions, all of whom had increased rates of hospitalization in our cohort.\u003C\/p\u003E\u003Cdiv id=\u0022sec-18\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003ELimitations\u003C\/h3\u003E\u003Cp id=\u0022p-46\u0022\u003EThis study has several limitations. The setting was a single health system and geographically limited to one US state with relatively low racial and ethnic minority representation, though it serves both urban and rural populations through academic and community hospitals. Even though we used statewide data for mortality and vaccination status, hospitalizations were collected only within one single health system. If mAb-untreated patients were less likely to be seen in this health system, hence more likely to be hospitalized elsewhere, this may bias our results toward the null. We also relied on EHR data, including manual chart reviews, which may have missing or inaccurate information about the presence of chronic conditions.[\u003Ca id=\u0022xref-ref-23-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-23\u0022\u003E23\u003C\/a\u003E] These factors might have limited our ability to detect the impact of sotrovimab treatment.\u003C\/p\u003E\u003Cp id=\u0022p-47\u0022\u003EWe only collected 28-day hospitalization and mortality data, and therefore we do not know whether sotrovimab effectiveness extends to a longer period after SARS-CoV-2 infection. However, our prior study would suggest that 28-day and 90-day data are similar with respect to hospitalization and mortality endpoints.[\u003Ca id=\u0022xref-ref-7-6\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-7\u0022\u003E7\u003C\/a\u003E] In this study, propensity scoring achieved excellent matching between mAb-treated and mAb-untreated patient groups across multiple variables, but unmeasured confounders may remain. Our EHR data does not contain information on SARS-CoV-2 variants at the patient level. However, during Colorado\u2019s Delta phase more than 99% of sequenced SARS-CoV-2 was Delta variant.[\u003Ca id=\u0022xref-ref-11-4\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-11\u0022\u003E11\u003C\/a\u003E]\u003C\/p\u003E\u003Cp id=\u0022p-48\u0022\u003EFinally, this study was conducted during a limited portion of the Delta variant-dominant period after sotrovimab drug distribution and infusion had been well-established in Colorado. In addition, hospitalization rates were lower over this same period, precluding our ability to perform inferential statistics on severity of illness among the hospitalized sub-cohort. Because the trend among the hospitalized subset strongly suggests sotrovimab benefit in reducing disease severity and hospital length of stay, examining sotrovimab effectiveness across US states during the same period would seemingly be an important next step to evaluate the generalizability of our findings. With the rapid emergence of the Omicron variant in mid-December 2021, our intent is to separately evaluate sotrovimab effectiveness against the omicron variant after enough treated and untreated cases have accrued. The Omicron variant has an abundance of mutations in the receptor-binding motif (RBM) of SARS-CoV-2, however in vitro reports suggest preserved neutralization of Omicron by sotrovimab,[\u003Ca id=\u0022xref-ref-24-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-24\u0022\u003E24\u003C\/a\u003E] potentially explained by its ability to target non-RBM epitopes shared across many sarbecoviruses, including SARS-CoV-1.\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-19\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EConclusion\u003C\/h2\u003E\u003Cp id=\u0022p-49\u0022\u003EThis study demonstrated real-world evidence for effectiveness of sotrovimab treatment in reducing hospitalizations among COVID-19 outpatients during the Delta variant phase, as well as a remarkable 89% overall reduction in mortality at 28 days, compared to matched mAb-untreated patients. For hospitalized patients, prior outpatient sotrovimab treatment may reduce respiratory disease severity, hospital length of stay, and death, but a larger cohort is necessary to further examine this observation. When access to mAbs is limited, prioritizing patients at highest risk for hospitalization has the most potential to reduce health system strain during the COVID-19 pandemic.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section data-availability\u0022 id=\u0022sec-21\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EData Availability\u003C\/h2\u003E\u003Cp id=\u0022p-50\u0022\u003EAll data produced in the present study are available upon reasonable request to the authors\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-22\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EFOOTNOTES\u003C\/h2\u003E\u003Col class=\u0022list-ord \u0022 id=\u0022list-1\u0022\u003E\u003Cli id=\u0022list-item-1\u0022\u003E\u003Cp id=\u0022p-51\u0022\u003EThe authors do not have a commercial or other association that might pose a conflict of interest (e.g., pharmaceutical stock ownership, consultancy, advisory board membership, relevant patents, or research funding)\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-2\u0022\u003E\u003Cp id=\u0022p-52\u0022\u003EThis study was funded by the National Center for Advancing Translational Sciences of the National Institutes of Health [grant numbers UL1TR002525, UL1TR002535-03S3 and UL1TR002535-04S2].\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-3\u0022\u003E\u003Cp id=\u0022p-53\u0022\u003EThis work has not been presented in part or in entirety at any meetings\u003C\/p\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section ref-list\u0022 id=\u0022ref-list-1\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EREFERENCES\u003C\/h2\u003E\u003Col class=\u0022cit-list ref-use-labels\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E1.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-1-1\u0022 title=\u0022View reference 1. in text\u0022 id=\u0022ref-1\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2022.04.03.22273360v1.1\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ECenters for Disease Control and Prevention\u003C\/span\u003E. \u003Cspan class=\u0022cit-source\u0022\u003EScience Brief: SARS-CoV-2 infection-induced and vaccine-induced immunity\u003C\/span\u003E. Available at: \u003Ca href=\u0022https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/science\/science-briefs\/vaccine-induced-immunity.html\u0022\u003Ehttps:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/science\/science-briefs\/vaccine-induced-immunity.html\u003C\/a\u003E). Accessed \u003Cspan class=\u0022cit-date-in-citation\u0022\u003EFebruary 10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E2.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-2-1\u0022 title=\u0022View reference 2. in text\u0022 id=\u0022ref-2\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2022.04.03.22273360v1.2\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ECOVID-19 Treatment Guidelines Panel\u003C\/span\u003E. \u003Cspan class=\u0022cit-source\u0022\u003ECoronavirus Disease 2019 (COVID-19) treatment guidelines. Available at\u003C\/span\u003E: \u003Ca href=\u0022https:\/\/www.covid19treatmentguidelines.nih.gov\u0022\u003Ehttps:\/\/www.covid19treatmentguidelines.nih.gov\u003C\/a\u003E. Accessed \u003Cspan class=\u0022cit-date-in-citation\u0022\u003EFebruary 10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E3.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-3-1\u0022 title=\u0022View reference 3. in text\u0022 id=\u0022ref-3\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2022.04.03.22273360v1.3\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDougan\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ENirula\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAzizad\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EBamlanivimab plus Etesevimab in Mild or Moderate Covid-19\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EN Engl J Med\u003C\/abbr\u003E \u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E; \u003Cspan class=\u0022cit-vol\u0022\u003E385\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E15\u003C\/span\u003E): \u003Cspan class=\u0022cit-fpage\u0022\u003E1382\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E92\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DN%2BEngl%2BJ%2BMed%26rft.volume%253D385%26rft.spage%253D1382%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F05%2F2022.04.03.22273360.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E4.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-4-1\u0022 title=\u0022View reference 4. in text\u0022 id=\u0022ref-4\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2022.04.03.22273360v1.4\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGupta\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGonzalez-Rojas\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EJuarez\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EEffect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJAMA\u003C\/abbr\u003E \u003Cspan class=\u0022cit-pub-date\u0022\u003E2022\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E5.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-5-1\u0022 title=\u0022View reference 5. in text\u0022 id=\u0022ref-5\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2022.04.03.22273360v1.5\u0022 data-doi=\u002210.1056\/nejmoa2035002\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWeinreich\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESivapalasingam\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ENorton\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EREGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EN Engl J Med\u003C\/abbr\u003E \u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E; \u003Cspan class=\u0022cit-vol\u0022\u003E384\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E3\u003C\/span\u003E): \u003Cspan class=\u0022cit-fpage\u0022\u003E238\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E51\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DN%2BEngl%2BJ%2BMed%26rft.volume%253D384%26rft.spage%253D238%26rft_id%253Dinfo%253Adoi%252F10.1056%252Fnejmoa2035002%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1056\/nejmoa2035002\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F05%2F2022.04.03.22273360.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E6.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-6-1\u0022 title=\u0022View reference 6. in text\u0022 id=\u0022ref-6\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2022.04.03.22273360v1.6\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELynch\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHF\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECaplan\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EFurlong\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBateman-House\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EHelpful Lessons and Cautionary Tales: How Should COVID-19 Drug Development and Access Inform Approaches to Non-Pandemic Diseases?\u003C\/span\u003E \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAm J Bioeth\u003C\/abbr\u003E \u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E; \u003Cspan class=\u0022cit-vol\u0022\u003E21\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E12\u003C\/span\u003E): \u003Cspan class=\u0022cit-fpage\u0022\u003E4\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E19\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DAm%2BJ%2BBioeth%26rft.volume%253D21%26rft.spage%253D4%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F05%2F2022.04.03.22273360.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E7.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-7-1\u0022 title=\u0022View reference 7. in text\u0022 id=\u0022ref-7\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2022.04.03.22273360v1.7\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWynia\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMK\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBeaty\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ELE\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBennett\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ETD\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EReal World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 Outpatients\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EmedRxiv\u003C\/abbr\u003E \u003Cspan class=\u0022cit-pub-date\u0022\u003E2022\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E8.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-8-1\u0022 title=\u0022View reference 8. in text\u0022 id=\u0022ref-8\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2022.04.03.22273360v1.8\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECavazzoni\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E, MD. \u003Cspan class=\u0022cit-article-title\u0022\u003ECoronavirus (COVID-19) Update: FDA Limits Use of Certain Monoclonal Antibodies to Treat COVID-19 Due to the Omicron Variant\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EIn: Administration FD\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2022\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E9.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-9-1\u0022 title=\u0022View reference 9. in text\u0022 id=\u0022ref-9\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2022.04.03.22273360v1.9\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EISPOR\u003C\/span\u003E. \u003Cspan class=\u0022cit-source\u0022\u003EAbout real-world evidence\u003C\/span\u003E. \u003Cspan class=\u0022cit-month\u0022\u003EDecember\u003C\/span\u003E \u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E. Available at: \u003Ca href=\u0022https:\/\/www.ispor.org\/strategic-initiatives\/real-world-evidence\/about-real-world-evidence\u0022\u003Ehttps:\/\/www.ispor.org\/strategic-initiatives\/real-world-evidence\/about-real-world-evidence\u003C\/a\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E10.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-10-1\u0022 title=\u0022View reference 10. in text\u0022 id=\u0022ref-10\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2022.04.03.22273360v1.10\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAngus\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDC\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EOptimizing the Trade-off Between Learning and Doing in a Pandemic\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJAMA\u003C\/abbr\u003E \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E; \u003Cspan class=\u0022cit-vol\u0022\u003E323\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E19\u003C\/span\u003E): \u003Cspan class=\u0022cit-fpage\u0022\u003E1895\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E6\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DJAMA%26rft.volume%253D323%26rft.spage%253D1895%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F05%2F2022.04.03.22273360.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E11.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-11-1\u0022 title=\u0022View reference 11. in text\u0022 id=\u0022ref-11\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2022.04.03.22273360v1.11\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EColorado Department of Public Health and Environment\u003C\/span\u003E. \u003Cspan class=\u0022cit-source\u0022\u003ETreatments for Covid-19. Available at\u003C\/span\u003E: \u003Ca href=\u0022https:\/\/covid19.colorado.gov\/for-coloradans\/covid-19-treatments#collapse-accordion-40911-4\u0022\u003Ehttps:\/\/covid19.colorado.gov\/for-coloradans\/covid-19-treatments#collapse-accordion-40911-4\u003C\/a\u003E. Accessed \u003Cspan class=\u0022cit-date-in-citation\u0022\u003EFebruary 10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E12.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-12-1\u0022 title=\u0022View reference 12. in text\u0022 id=\u0022ref-12\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2022.04.03.22273360v1.12\u0022 data-doi=\u002210.1080\/00273171.2011.568786\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAustin\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPC\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EAn Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EMultivariate Behav Res\u003C\/abbr\u003E \u003Cspan class=\u0022cit-pub-date\u0022\u003E2011\u003C\/span\u003E; \u003Cspan class=\u0022cit-vol\u0022\u003E46\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E3\u003C\/span\u003E): \u003Cspan class=\u0022cit-fpage\u0022\u003E399\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E424\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.stitle%253DMultivariate%2BBehav%2BRes%26rft.aulast%253DAustin%26rft.auinit1%253DP.%2BC.%26rft.volume%253D46%26rft.issue%253D3%26rft.spage%253D399%26rft.epage%253D424%26rft.atitle%253DAn%2BIntroduction%2Bto%2BPropensity%2BScore%2BMethods%2Bfor%2BReducing%2Bthe%2BEffects%2Bof%2BConfounding%2Bin%2BObservational%2BStudies.%26rft_id%253Dinfo%253Adoi%252F10.1080%252F00273171.2011.568786%26rft_id%253Dinfo%253Apmid%252F21818162%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1080\/00273171.2011.568786\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=21818162\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F05%2F2022.04.03.22273360.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=000291533400002\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E13.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-13-1\u0022 title=\u0022View reference 13. in text\u0022 id=\u0022ref-13\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2022.04.03.22273360v1.13\u0022 data-doi=\u002210.1093\/pan\/mpl013\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDaniel Ho\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKI\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EGary\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKing\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EElizabeth\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EStuart.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EMatching as Nonparametric Preprocessing for Reducing Model Dependence in Parametric Causal Inference\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EPolitical Analysis\u003C\/abbr\u003E \u003Cspan class=\u0022cit-pub-date\u0022\u003E2007\u003C\/span\u003E; \u003Cspan class=\u0022cit-vol\u0022\u003E15\u003C\/span\u003E: \u003Cspan class=\u0022cit-fpage\u0022\u003E199\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E236\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DPolitical%2BAnalysis%26rft_id%253Dinfo%253Adoi%252F10.1093%252Fpan%252Fmpl013%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1093\/pan\/mpl013\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=000248544000002\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E14.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-14-1\u0022 title=\u0022View reference 14. in text\u0022 id=\u0022ref-14\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2022.04.03.22273360v1.14\u0022 data-doi=\u002210.1002\/sim.3697\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAustin\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPC\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EBalance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EStat Med\u003C\/abbr\u003E \u003Cspan class=\u0022cit-pub-date\u0022\u003E2009\u003C\/span\u003E; \u003Cspan class=\u0022cit-vol\u0022\u003E28\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E25\u003C\/span\u003E): \u003Cspan class=\u0022cit-fpage\u0022\u003E3083\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E107\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DStatistics%2Bin%2Bmedicine%26rft.stitle%253DStat%2BMed%26rft.aulast%253DAustin%26rft.auinit1%253DP.%2BC.%26rft.volume%253D28%26rft.issue%253D25%26rft.spage%253D3083%26rft.epage%253D3107%26rft.atitle%253DBalance%2Bdiagnostics%2Bfor%2Bcomparing%2Bthe%2Bdistribution%2Bof%2Bbaseline%2Bcovariates%2Bbetween%2Btreatment%2Bgroups%2Bin%2Bpropensity-score%2Bmatched%2Bsamples.%26rft_id%253Dinfo%253Adoi%252F10.1002%252Fsim.3697%26rft_id%253Dinfo%253Apmid%252F19757444%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1002\/sim.3697\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=19757444\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F05%2F2022.04.03.22273360.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=000271409300008\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E15.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-15-1\u0022 title=\u0022View reference 15. in text\u0022 id=\u0022ref-15\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2022.04.03.22273360v1.15\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ENational Institute of Health Covid treatment guidelines\u003C\/span\u003E. \u003Cspan class=\u0022cit-source\u0022\u003EClinical spectrum of SARS-CoV-2 infection\u003C\/span\u003E.. Available at: \u003Ca href=\u0022http:\/\/www.covid19treatmentguidelines.nih.gov\/overview\/clinical-spectrum\u0022\u003E\/\/www.covid19treatmentguidelines.nih.gov\/overview\/clinical-spectrum\u003C\/a\u003E. Accessed \u003Cspan class=\u0022cit-date-in-citation\u0022\u003EFebruary 10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E16.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-16-1\u0022 title=\u0022View reference 16. in text\u0022 id=\u0022ref-16\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2022.04.03.22273360v1.16\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGeorg Heinze\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMPaLJ.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003Elogistf: Firth\u2019s Bias-Reduced Logistic Regression\u003C\/span\u003E. \u003Cspan class=\u0022cit-source\u0022\u003ER package version 1.24\u003C\/span\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E17.\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2022.04.03.22273360v1.17\u0022 data-doi=\u002210.1002\/sim.1047\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHeinze\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESchemper\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EA solution to the problem of separation in logistic regression\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EStat Med\u003C\/abbr\u003E \u003Cspan class=\u0022cit-pub-date\u0022\u003E2002\u003C\/span\u003E; \u003Cspan class=\u0022cit-vol\u0022\u003E21\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E16\u003C\/span\u003E): \u003Cspan class=\u0022cit-fpage\u0022\u003E2409\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E19\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DStatistics%2Bin%2Bmedicine%26rft.stitle%253DStat%2BMed%26rft.aulast%253DHeinze%26rft.auinit1%253DG.%26rft.volume%253D21%26rft.issue%253D16%26rft.spage%253D2409%26rft.epage%253D2419%26rft.atitle%253DA%2Bsolution%2Bto%2Bthe%2Bproblem%2Bof%2Bseparation%2Bin%2Blogistic%2Bregression.%26rft_id%253Dinfo%253Adoi%252F10.1002%252Fsim.1047%26rft_id%253Dinfo%253Apmid%252F12210625%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1002\/sim.1047\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=12210625\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F05%2F2022.04.03.22273360.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=000177458600011\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E18.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-18-1\u0022 title=\u0022View reference 18. in text\u0022 id=\u0022ref-18\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2022.04.03.22273360v1.18\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPuhr\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHeinze\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ENold\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELusa\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGeroldinger\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EFirth\u2019s logistic regression with rare events: accurate effect estimates and predictions?\u003C\/span\u003E \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EStat Med\u003C\/abbr\u003E \u003Cspan class=\u0022cit-pub-date\u0022\u003E2017\u003C\/span\u003E; \u003Cspan class=\u0022cit-vol\u0022\u003E36\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E14\u003C\/span\u003E): \u003Cspan class=\u0022cit-fpage\u0022\u003E2302\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E17\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DStat%2BMed%26rft.volume%253D36%26rft.spage%253D2302%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E19.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-19-1\u0022 title=\u0022View reference 19. in text\u0022 id=\u0022ref-19\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-book\u0022 id=\u0022cit-2022.04.03.22273360v1.19\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ETeam RC\u003C\/span\u003E. \u003Cspan class=\u0022cit-source\u0022\u003ER: a language and environment for statistical computing\u003C\/span\u003E. \u003Cspan class=\u0022cit-publ-loc\u0022\u003EVienna\u003C\/span\u003E: \u003Cspan class=\u0022cit-publ-name\u0022\u003ER Foundation for Statistical Computing\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E20.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-20-1\u0022 title=\u0022View reference 20. in text\u0022 id=\u0022ref-20\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2022.04.03.22273360v1.20\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECameroni\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESaliba\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBowen\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJE\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EBroadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EbioRxiv\u003C\/abbr\u003E \u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E21.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-21-1\u0022 title=\u0022View reference 21. in text\u0022 id=\u0022ref-21\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2022.04.03.22273360v1.21\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-source\u0022\u003EStrategies to allocate scarce COVID-19 monoclonal antibody treatments to eligible patients examined in new rapid response to government\u003C\/span\u003E. \u003Cspan class=\u0022cit-month\u0022\u003EJanuary\u003C\/span\u003E \u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E. Available at: \u003Ca href=\u0022https:\/\/www.nationalacademies.org\/news\/2021\/01\/strategies-to-allocate-scarce-covid-19-monoclonal-antibody-treatments-to-eligible-patients-examined-in-new-rapid-response-to-government\u0022\u003Ehttps:\/\/www.nationalacademies.org\/news\/2021\/01\/strategies-to-allocate-scarce-covid-19-monoclonal-antibody-treatments-to-eligible-patients-examined-in-new-rapid-response-to-government\u003C\/a\u003E). Accessed \u003Cspan class=\u0022cit-date-in-citation\u0022\u003EFebruary 10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E22.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-22-1\u0022 title=\u0022View reference 22. in text\u0022 id=\u0022ref-22\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2022.04.03.22273360v1.22\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBernstein\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL.\u003C\/span\u003E\u003C\/span\u003E \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBiden Administration moves to stave off shortages of monoclonal antibodies\u003C\/abbr\u003E. Accessed \u003Cspan class=\u0022cit-date-in-citation\u0022\u003EFebruary 10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E23.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-23-1\u0022 title=\u0022View reference 23. in text\u0022 id=\u0022ref-23\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2022.04.03.22273360v1.23\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBennett\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ETD\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMoffitt\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ERA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHajagos\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJG\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EClinical Characterization and Prediction of Clinical Severity of SARS-CoV-2 Infection Among US Adults Using Data From the US National COVID Cohort Collaborative\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJAMA Netw Open\u003C\/abbr\u003E \u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E; \u003Cspan class=\u0022cit-vol\u0022\u003E4\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E7\u003C\/span\u003E): \u003Cspan class=\u0022cit-fpage\u0022\u003Ee2116901\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DJAMA%2BNetw%2BOpen%26rft.volume%253D4%26rft.spage%253D2116901e%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E24.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-24-1\u0022 title=\u0022View reference 24. in text\u0022 id=\u0022ref-24\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2022.04.03.22273360v1.24\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EVanBlargan\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ELA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EErrico\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHalfmann\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EAn infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ENat Med\u003C\/abbr\u003E \u003Cspan class=\u0022cit-pub-date\u0022\u003E2022\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003C\/div\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan class=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/js\/js_zP7WWIfzbyzvaM63L39cNV2juU_1XVH7wduFK9gcMNI.js\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}